Please assess the completion status of the following clinical trial:

Trial Title: Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Residence in the study site~* Able to understand the information and willing to give consent and assent (parent or guardian consent if study participant age is \< 18 years)~Exclusion Criteria:~* Residence outside of in the study site~* Height ≤ 90 cm~* Permanent disability, serious medical illness that prevents or impedes study participation and/or comprehension~* Pregnancy~* Breast feeding if infant is within 1 week of birth~* Known allergy to the study drugs

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Single MDA (Type: ACTIVE_COMPARATOR): Single mass drug administration of ivermectin (150 µg/kg) + albendazole (400 mg) performed after the start of the rainy season as part of public health efforts to eliminate lymphatic filariasis.
- Repeated MDA (Type: EXPERIMENTAL): Same at Active Comparator, but then followed by five more mass drug administrations of ivermectin only (150 µg/kg) every three weeks thereafter.

Based on this trial design, predict the completion outcome and termination type (if applicable).